CA3155930A1 - Domaines de liaison a l'antigene associes a des cellules senescentes, anticorps et recepteurs antigeniques chimeriques les comprenant, et leurs utilisations - Google Patents

Domaines de liaison a l'antigene associes a des cellules senescentes, anticorps et recepteurs antigeniques chimeriques les comprenant, et leurs utilisations

Info

Publication number
CA3155930A1
CA3155930A1 CA3155930A CA3155930A CA3155930A1 CA 3155930 A1 CA3155930 A1 CA 3155930A1 CA 3155930 A CA3155930 A CA 3155930A CA 3155930 A CA3155930 A CA 3155930A CA 3155930 A1 CA3155930 A1 CA 3155930A1
Authority
CA
Canada
Prior art keywords
seq
binding domain
dpp4
hcvr
dep1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3155930A
Other languages
English (en)
Inventor
Muge Ogrunc
Thierry MATHIEU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Starkage Therapeutics SA
Original Assignee
MATHIEU, Thierry
OGRUNC, MUGE
Starkage Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/585,256 external-priority patent/US20210093665A1/en
Application filed by MATHIEU, Thierry, OGRUNC, MUGE, Starkage Therapeutics SA filed Critical MATHIEU, Thierry
Publication of CA3155930A1 publication Critical patent/CA3155930A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464458—Proteinases
    • A61K39/46446—Serine proteases, e.g. kallikrein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464463—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des domaines de liaison à DEP1 et des domaines de liaison à DPP4, ainsi que des anticorps et des récepteurs antigéniques chimériques (CAR) les comprenant. L'invention concerne également des utilisations et des procédés pour traiter, prévenir ou soulager des maladies ou des troubles liés à la sénescence, ou pour dépléter et/ou tuer des cellules sénescentes.
CA3155930A 2019-09-27 2020-09-25 Domaines de liaison a l'antigene associes a des cellules senescentes, anticorps et recepteurs antigeniques chimeriques les comprenant, et leurs utilisations Pending CA3155930A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19200182 2019-09-27
US16/585,256 US20210093665A1 (en) 2019-09-27 2019-09-27 Chimeric antigen receptors against senescent cells and uses thereof
PCT/EP2020/076995 WO2021058795A2 (fr) 2019-09-27 2020-09-25 Domaines de liaison à l'antigène associés à des cellules sénescentes, anticorps et récepteurs antigéniques chimériques les comprenant, et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3155930A1 true CA3155930A1 (fr) 2021-04-01

Family

ID=72811789

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3155930A Pending CA3155930A1 (fr) 2019-09-27 2020-09-25 Domaines de liaison a l'antigene associes a des cellules senescentes, anticorps et recepteurs antigeniques chimeriques les comprenant, et leurs utilisations

Country Status (3)

Country Link
EP (1) EP4034561A2 (fr)
CA (1) CA3155930A1 (fr)
WO (1) WO2021058795A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805587B (zh) * 2022-06-10 2023-11-28 清华大学 Car-nk细胞及其在脏器和组织老化与纤维化治疗中的用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2001062895A2 (fr) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Stimulation et concentration simultanees de cellules
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2401621A1 (fr) * 2000-03-01 2001-09-07 Vanderbilt University Modulation de l'activite des recepteurs de surface des cellules endotheliales dans la regulation de l'angiogenese
EP1916303B1 (fr) 2000-11-30 2013-02-27 Medarex, Inc. Acides nucléiques codant des séquences d'immunoglobulines humaines réarrangées obtenus de souris transgéniques chromosomales
CN100341572C (zh) * 2001-05-11 2007-10-10 得克萨斯州立大学董事会 抗cd26单克隆抗体作为对与表达cd26的细胞相关疾病的治疗
US20050287140A1 (en) * 2004-04-23 2005-12-29 Amgen Inc. Antibodies to angiogenesis inhibiting domains of CD148
JP4997239B2 (ja) * 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体およびその使用方法
AU2008259939B2 (en) 2007-06-01 2014-03-13 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
JP2015030666A (ja) * 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
EP3344263A4 (fr) * 2016-08-04 2020-07-01 Memorial Sloan-Kettering Cancer Center Cibles d'antigène du cancer et leurs utilisations
CA3054808A1 (fr) * 2017-02-28 2018-09-07 Vor Biopharma, Inc. Compositions et methodes d'inhibition de proteines specifiques d'une lignee

Also Published As

Publication number Publication date
WO2021058795A3 (fr) 2021-05-27
EP4034561A2 (fr) 2022-08-03
WO2021058795A2 (fr) 2021-04-01

Similar Documents

Publication Publication Date Title
CN111526888B (zh) 抗tigit抗体及其作为治疗和诊断的用途
US10889652B2 (en) Antibodies and chimeric antigen receptors specific for ROR1
CA2960650C (fr) Agent therapeutique induisant une cytotoxicite
US20190077872A1 (en) Method for enhancing humoral immune response
KR20180072820A (ko) 항-il1rap 항체, il1rap 및 cd3과 결합하는 이중특이성 항원 결합 분자, 및 그의 용도
TW201735947A (zh) 用於癌之治療的細胞傷害誘導治療劑
AU2017205900B2 (en) Therapeutic anti-CD9 antibody
KR20220147631A (ko) 면역 반응을 조절하기 위한 물질 및 방법
WO2020135559A1 (fr) Fractions de liaison à cd30, récepteurs d'antigènes chimériques et leurs utilisations
WO2021170100A1 (fr) Anticorps et récepteurs antigéniques chimériques ciblant le glypicane-3 (gpc3) et leurs procédés d'utilisation
EP4245855A1 (fr) Anticorps bispécifique anti-tspan8-anti-cd3 et anticorps anti-tspan8
US20240009242A1 (en) Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
CA3155930A1 (fr) Domaines de liaison a l'antigene associes a des cellules senescentes, anticorps et recepteurs antigeniques chimeriques les comprenant, et leurs utilisations
US20210093665A1 (en) Chimeric antigen receptors against senescent cells and uses thereof
JP2024506682A (ja) 抗ＴＣＲδ鎖可変部１抗体
US20240033356A1 (en) Chimeric antigen receptor t cell and method
WO2024046468A1 (fr) Protéines de fusion ciblant la voie de dégradation lysosomale
WO2024026471A1 (fr) Domaines de liaison à l'antigène cd98hc et leurs utilisations